Needle-free Injection has been accepted by Chinese Medical Insurance. Establish cooperation with Medicine Manufacturer to study vaccine injection.
Launched QS-K in Chinese Market.
Finished clinical study and published on Lancet, this was the first clinical trial related to NFIs in the world involved in over 400 diabetic patients.
Launched QS-P in Chinese market. QS-K was developed and gained Reddot Design Award.
Gained CE & ISO on QS-M & QS-P, CFDA on QS-P.
QS-M gained Reddot Design Award and Red Star Design Award.
QS Medical was approved as Chinese High-tech Enterprise, QS-P was developed.
QS-M achieved CFDA approval.
QS Medical transition to Quinovare, QS-M was developed.
Needle-free injector research center was set up.